Analysts at Roth Capital began coverage on shares of InfuSystem (NYSE:INFU - Get Free Report) in a report released on Tuesday, MarketBeat.com reports. The firm set a "buy" rating and a $12.00 price target on the stock. Roth Capital's target price indicates a potential upside of 111.45% from the stock's previous close.
INFU has been the subject of a number of other reports. Wall Street Zen downgraded InfuSystem from a "strong-buy" rating to a "buy" rating in a report on Wednesday, May 14th. B. Riley upgraded InfuSystem to a "strong-buy" rating in a research note on Thursday, May 8th.
Check Out Our Latest Stock Report on InfuSystem
InfuSystem Trading Up 3.0%
Shares of NYSE INFU traded up $0.17 during midday trading on Tuesday, hitting $5.68. The stock had a trading volume of 26,066 shares, compared to its average volume of 153,097. The company has a market capitalization of $119.27 million, a price-to-earnings ratio of 94.60 and a beta of 1.81. InfuSystem has a 1-year low of $4.61 and a 1-year high of $9.97. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The company has a fifty day moving average price of $5.95 and a 200 day moving average price of $6.34.
Institutional Investors Weigh In On InfuSystem
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its holdings in shares of InfuSystem by 67.9% in the 4th quarter. BNP Paribas Financial Markets now owns 6,844 shares of the company's stock valued at $58,000 after purchasing an additional 2,768 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of InfuSystem in the first quarter worth $58,000. Wells Fargo & Company MN boosted its holdings in InfuSystem by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,286 shares of the company's stock worth $78,000 after buying an additional 3,165 shares in the last quarter. Summit Global Investments acquired a new position in InfuSystem during the fourth quarter worth $86,000. Finally, Virtu Financial LLC acquired a new position in InfuSystem during the first quarter worth $86,000. Hedge funds and other institutional investors own 71.13% of the company's stock.
About InfuSystem
(
Get Free Report)
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InfuSystem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.
While InfuSystem currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
